Hypertrophic Cardiomyopathy 2 (TNNT2-related HCM): Disease Characteristics Report

Executive scope and evidence note

Hypertrophic cardiomyopathy 2 (HCM2) is the historical gene-numbered form of familial hypertrophic cardiomyopathy caused by heterozygous pathogenic variants in TNNT2, encoding cardiac troponin T. It should not be confused with generic hypertrophic cardiomyopathy (HCM), nor with other TNNT2-associated phenotypes such as dilated cardiomyopathy or left-ventricular noncompaction. Open Targets supports a literature-backed association between TNNT2 (ENSG00000118194) and HCM/familial HCM, including primary reports indexed by PMIDs 8989109, 10525521, 12707239, 27532257, 28369730, and 30681346. (OpenTargets Search: hypertrophic cardiomyopathy-TNNT2)

Because contemporary guidelines generally manage disease according to the HCM phenotype, rather than its historical numbered subtype, this report labels evidence as either TNNT2-specific or general-HCM extrapolation. The source base is aggregated disease-level literature rather than individual-patient EHR data.

Table: This compact table summarizes key facts for Hypertrophic Cardiomyopathy 2 as TNNT2-related HCM, with ontology suggestions and evidence qualifiers for direct knowledge-base ingestion. It distinguishes TNNT2-specific findings from general-HCM extrapolations and flags uncertain identifiers to avoid over-assertion.

1. Disease information

HCM2 is a primary sarcomeric myocardial disorder characterized by otherwise unexplained left-ventricular hypertrophy (LVH), cardiomyocyte disarray, diastolic dysfunction, and variable susceptibility to ventricular arrhythmia, heart failure, and sudden cardiac death. TNNT2 disease is notable because substantial arrhythmic risk may occur with relatively modest hypertrophy. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2, cai2020establishinganew pages 21-25)

Identifiers and nomenclature

• Historical identifier: OMIM 115195, Cardiomyopathy, familial hypertrophic, 2.
• Gene: TNNT2, HGNC:11949; Ensembl ENSG00000118194; cardiac troponin T.
• Broad phenotype: MONDO:0005045, hypertrophic cardiomyopathy; MONDO:0024573, familial hypertrophic cardiomyopathy. A confidently verified HCM2-specific MONDO identifier was not recovered, so the broad MONDO term plus TNNT2 genotype is preferable. (OpenTargets Search: hypertrophic cardiomyopathy-TNNT2)
• Common synonyms: TNNT2-related hypertrophic cardiomyopathy, cardiac troponin T-associated HCM, familial hypertrophic cardiomyopathy due to TNNT2, and HCM2.
• ICD-10/ICD-11 and MeSH generally encode HCM or obstructive HCM, not the TNNT2 subtype; genotype should therefore be recorded separately.

2. Etiology, risk, protection, and gene–environment interaction

Primary cause

The causal lesion is usually a heterozygous germline TNNT2 pathogenic or likely pathogenic variant. TNNT2 is a component of the troponin complex on the sarcomeric thin filament and couples cytosolic calcium signals to actin–myosin contraction. Reported HCM-associated classes include missense substitutions and small in-frame deletions, including p.Ile79Asn (I79N), p.Arg92Gln (R92Q), and p.Glu160del (Δ160E; c.478_480del). (kondo2022humaninducedpluripotentstem pages 1-2, shafaattalab2021mechanismsofarrhythmogenicity pages 1-2, cai2020establishinganew pages 21-25)

Risk modifiers

Risk is shaped by variant-specific biophysics, age, family history, polygenic background, sex, loading conditions, and lifestyle, but robust TNNT2-specific effect sizes are limited. The best recent synthesis concludes that penetrance is “highly variable” and influenced by still-undefined, context-dependent genetic and environmental factors. In family-based cascade screening, TNNT2 penetrance was approximately 60%, whereas penetrance of incidentally discovered sarcomeric variants in population cohorts was much lower, approximately 11% overall. (topriceanu2024metaanalysisofpenetrance pages 1-2)

Hypertension, obesity, intense adrenergic stress, dehydration, and extreme exertion can worsen the expressed HCM phenotype or provoke obstruction/arrhythmia, but they do not cause monogenic HCM2. Family history of premature sudden death is clinically important. No infectious cause is recognized.

Protective factors

No validated TNNT2-specific protective allele is established. Potentially protective management includes blood-pressure control, avoidance of dehydration and stimulant misuse, individualized exercise counseling, and surveillance of genotype-positive relatives. Experimental calcium desensitization improved abnormal calcium decay and relaxation in TNNT2-Δ160E cardiomyocytes, but this is not established preventive therapy. (kondo2022humaninducedpluripotentstem pages 1-2, sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12)

3. Phenotypes

Clinical expression is age-dependent and highly variable, ranging from lifelong genotype-positive/phenotype-negative status to childhood or adult disease, severe arrhythmia, heart failure, or sudden death. Mean age at diagnosis among nonproband sarcomeric-variant relatives was 38 years (95% CI 36–40); this is not a TNNT2-only age estimate. (topriceanu2024metaanalysisofpenetrance pages 1-2)

Major phenotypes and suggested HPO annotations include:

• Left-ventricular hypertrophy — HP:0001712: usually asymmetric septal, but apical or concentric patterns may occur. Severity is variable; TNNT2 carriers may have mild hypertrophy despite clinically important arrhythmic risk. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2, nakamura2025cardiacmyosininhibitors pages 2-4)
• Abnormal LV diastolic function — HP:0005157: impaired relaxation is mechanistically early and may precede overt hypertrophy. TNNT2-Δ160E cells showed prolonged calcium decay and relaxation impairment. (kondo2022humaninducedpluripotentstem pages 1-2)
• Ventricular arrhythmia — HP:0001680; arrhythmia — HP:0001645: palpitations, nonsustained or sustained ventricular tachycardia, and fibrillation may occur. I79N cardiomyocytes developed action-potential and calcium alternans above 75 beats/min in vitro. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2)
• Syncope — HP:0001279/HP:0001644 depending local mapping: may reflect obstruction or arrhythmia and is a sudden-death risk marker.
• Sudden cardiac death — HP:0001699: a major but incompletely predictable complication, sometimes disproportionate to wall thickness in TNNT2 disease. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2)
• Dyspnea, chest pain, fatigue, reduced exercise tolerance: generally progressive with obstruction, diastolic dysfunction, microvascular ischemia, or heart failure; subtype-specific frequencies were not recovered.
• Dynamic LV outflow-tract obstruction: provoked or resting obstruction may produce exertional symptoms; it is not universal and is not uniquely TNNT2-associated. (nakamura2025cardiacmyosininhibitors pages 2-4)
• Atrial enlargement/atrial fibrillation: downstream of chronic filling-pressure elevation; carries thromboembolic risk.
• Myocardial fibrosis and myofiber disarray: pathological substrates for stiffness and electrical instability. TNNT2 I79N models upregulated extracellular-matrix programs, while R92Q models showed altered sarcomere organization. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2, cai2020establishinganew pages 21-25)
• Systolic dysfunction/end-stage remodeling: uncommon but important; Δ160E was identified in familial HCM progressing to advanced heart failure. (kondo2022humaninducedpluripotentstem pages 1-2)

Quality of life is chiefly impaired through exercise limitation, symptoms, anxiety concerning sudden death, activity restrictions, repeated surveillance, and family implications. In obstructive HCM, mavacamten improved the Kansas City Cardiomyopathy Questionnaire overall score by 14.9 versus 5.4 points with placebo; 36% achieved a ≥20-point improvement, corresponding to an NNT of approximately 5. These data are HCM-wide, not TNNT2-specific. (nakamura2025cardiacmyosininhibitors pages 13-14)

4. Genetic and molecular information

Causal gene: TNNT2 encodes cardiac troponin T, a sarcomeric thin-filament protein. Pathogenic HCM variants are predominantly heterozygous germline missense or in-frame changes and commonly exert altered-function/“poison-peptide” effects rather than simple whole-gene haploinsufficiency. Variant interpretation must follow ACMG/AMP criteria using segregation, population frequency, computational, functional, and case-enrichment evidence.

Illustrative variants include:

• p.Ile79Asn: increases myofilament Ca²⁺ sensitivity, slows Ca²⁺ dissociation, and creates pro-arrhythmic electrophysiology. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2)
• p.Arg92Gln: produces calcium dysregulation, increased adrenergic sensitivity, hypertrophic-marker induction, and sarcomere disorganization in engineered human cardiomyocytes. (cai2020establishinganew pages 21-25)
• p.Glu160del/Δ160E: causes calcium retention, impaired relaxation, hypertrophic NFAT signaling, and in some families progressive systolic dysfunction. It was reported in 1/112 Japanese familial cases, 1/197 French cases, and 3/552 UK cases in the cited study’s background. (kondo2022humaninducedpluripotentstem pages 1-2)

Pathogenic HCM alleles should generally be absent or extremely rare in gnomAD; however, no universal allele-frequency value applies. Exact ClinVar classification and gnomAD frequency must be recorded per HGVS allele and transcript. VUSs are not suitable for predictive cascade testing or irreversible management decisions.

No recurrent chromosomal abnormality, repeat expansion, mitochondrial mutation, or somatic mechanism defines HCM2. Modifier genes and polygenic background likely contribute to penetrance, but no modifier is currently sufficiently validated for routine HCM2 risk prediction. Epigenetic abnormalities are biologically plausible downstream responses, but no diagnostic HCM2 methylation signature is established.

5. Environmental and lifestyle information

HCM2 is not caused by pollution, radiation, toxins, occupation, diet, or infection. Environmental/loading factors instead modify expression. Hypertension and obesity add hypertrophic and hemodynamic stress; dehydration and vasodilation may worsen LV outflow obstruction; intense adrenergic activation may reveal arrhythmia susceptibility. Mild-to-moderate recreational exercise is generally encouraged, while high-intensity or competitive exercise requires shared decision-making and is discouraged in individuals with major risk markers or significant obstruction. (sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12)

Smoking cessation, moderation of alcohol, maintenance of healthy weight, treatment of sleep apnea and hypertension, and avoidance of illicit stimulants are prudent cardiovascular measures, although none has proven TNNT2-specific disease-preventing efficacy.

6. Mechanism and pathophysiology

Causal chain

TNNT2 variant → altered troponin–tropomyosin/actin regulation → increased thin-filament calcium sensitivity and slower calcium release → hypercontractility and impaired lusitropy → energetic demand–supply mismatch and calcium-handling instability → hypertrophic signaling, cardiomyocyte enlargement, disarray, extracellular-matrix remodeling and fibrosis → diastolic dysfunction, obstruction, ischemia, arrhythmia, and occasionally systolic failure.

The I79N study directly found increased calcium sensitivity and reduced Ca²⁺ off-rate. Its abstract reports that these changes caused “beat-to-beat instability and triangulation of the cardiac action potential,” while NPPA, NPPB, Notch, and ECM-remodeling genes were upregulated. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2)

In Δ160E cardiomyocytes, calcium retention and delayed relaxation activated CaMKIIδ, phospholamban phosphorylation, and dose-dependent NFATc1 nuclear translocation, linking the biophysical lesion to hypertrophic gene expression. Calcium desensitization with epigallocatechin-3-gallate partially rescued relaxation in vitro. (kondo2022humaninducedpluripotentstem pages 1-2)

Biological annotations

• Processes: sarcomere organization; cardiac muscle contraction (GO:0060048); muscle filament sliding (GO:0030049); regulation of cytosolic Ca²⁺ (GO:0051480); cardiac action potential (GO:0086001); protein phosphorylation (GO:0006468); response to oxidative stress (GO:0006979); ECM organization (GO:0030198).
• Cells: cardiomyocyte (CL:0002494) is primary; cardiac fibroblasts (CL:0000057, broad fibroblast) and endothelial/immune cells participate secondarily in remodeling.
• Compartments: sarcomere (GO:0030017), myofilament/thin filament, cytosol, sarcoplasmic reticulum, mitochondrion, and nucleus.

Recent model work also implicates mitochondrial redox imbalance: increased myofilament calcium sensitivity can uncouple workload from mitochondrial calcium signaling, consume NADPH-dependent antioxidant reserve, increase mitochondrial ROS, trigger spontaneous sarcoplasmic-reticulum calcium release, and slow conduction. This provides both trigger and substrate for arrhythmia, but the 2024 report was preprint-stage and is not yet a clinical biomarker or therapy. (dolder2025experimentalmodelsof pages 36-36)

Single-cell, spatial-transcriptomic, proteomic, metabolomic, or lipidomic signatures specific to TNNT2-HCM2 remain insufficiently validated for clinical use. Current omics findings are largely experimental and variant/model dependent.

7. Anatomical structures affected

The primary organ is the heart (UBERON:0000948), especially left-ventricular myocardium (UBERON:0002084, myocardium; UBERON:0002080, cardiac ventricle). Hypertrophy may involve the interventricular septum, apex, free wall, papillary muscles, and mitral–septal apparatus; dynamic obstruction localizes to the LV outflow tract. Secondary involvement includes left-atrial enlargement, pulmonary venous hypertension, and systemic thromboembolism from atrial fibrillation.

At tissue level, cardiac muscle shows cardiomyocyte hypertrophy, sarcomere/myofiber disarray, small-vessel disease, and interstitial or replacement fibrosis. At subcellular level, the thin filament, calcium-handling apparatus, mitochondria, and hypertrophic-signaling nucleus are implicated. Disease is not lateralized; ventricular distribution may be asymmetric. (kondo2022humaninducedpluripotentstem pages 1-2, shafaattalab2021mechanismsofarrhythmogenicity pages 1-2, cai2020establishinganew pages 21-25)

8. Temporal development

HCM2 is a chronic lifelong genetic predisposition, often clinically silent for years. Onset can occur in childhood, adolescence, or adulthood; penetrance is age-dependent rather than congenital in every carrier. In the 2024 meta-analysis, mean HCM diagnosis age among nonproband carriers was 38 years, and longitudinal family cohorts showed approximately 15% phenotypic conversion over eight years, beginning from a mean age near 16 years. TNNT2 penetrance was approximately 60% in family-screened relatives. (topriceanu2024metaanalysisofpenetrance pages 1-2)

A useful stage model is:

1. Genotype-positive/phenotype-negative: normal wall thickness; subtle ECG, strain, diastolic, or biomarker abnormalities may occur.
2. Early phenotype: focal hypertrophy and impaired relaxation.
3. Established HCM: symptomatic or asymptomatic hypertrophy, with or without LVOTO.
4. Complicated HCM: atrial fibrillation, ventricular arrhythmia, progressive fibrosis, stroke, or heart failure.
5. End-stage disease: systolic dysfunction, restrictive physiology, or transplant-level failure in a minority.

There is no spontaneous genetic remission. Obstruction and symptoms can improve with treatment, but pathogenic-variant status persists. Childhood growth, athletic exposure, pregnancy, hypertension, and aging are clinically important surveillance periods.

9. Inheritance and population

Inheritance is usually autosomal dominant, with a 50% transmission probability from a heterozygous affected parent. Penetrance is incomplete and age-dependent, and expressivity is highly variable—even within a family. Genetic anticipation is not established. Germline mosaicism is possible in principle but is not a defining feature; consanguinity is not generally relevant to dominant HCM2. (topriceanu2024metaanalysisofpenetrance pages 1-2)

The classic clinical prevalence of all HCM is approximately 1 in 500, but contemporary genotype/imaging estimates vary. HCM-associated P/LP variants may be more common than clinically expressed disease. HCM2-specific prevalence and incidence per 100,000 are not robustly established, and TNNT2 is a minority cause compared with MYBPC3 and MYH7. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2, topriceanu2024metaanalysisofpenetrance pages 1-2)

No consistent ethnicity-specific or geographic distribution applies to TNNT2-HCM as a whole. Individual founder alleles may be enriched locally and should be assessed variant by variant. Both sexes inherit variants equally, although clinical expression and outcomes may differ by sex; no reliable HCM2-specific male:female ratio was recovered.

10. Diagnostics

Clinical and imaging criteria

In adults, HCM is generally diagnosed by otherwise unexplained maximum LV wall thickness ≥15 mm; ≥13 mm may support diagnosis in a first-degree relative or known pathogenic-variant carrier. Echocardiography is first-line. Valsalva, standing, or exercise provocation is used to detect latent obstruction when the resting gradient is absent. Cardiac MRI clarifies apical or focal hypertrophy and identifies aneurysm, thrombus, and late-gadolinium-enhancement fibrosis. (sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12, nakamura2025cardiacmyosininhibitors pages 2-4)

Baseline evaluation includes history and pedigree, physical examination, 12-lead ECG, ambulatory ECG, echocardiography, exercise testing when appropriate, and CMR. NT-proBNP and cardiac troponin reflect hemodynamic stress/injury and prognosis but are not HCM2-specific diagnostic tests.

Histology, usually available only after myectomy, transplant, or autopsy, may show cardiomyocyte hypertrophy, nuclear enlargement, myofiber disarray, and fibrosis. Biopsy is not routinely needed for typical sarcomeric HCM.

Genetic testing

Recommended testing uses a validated cardiomyopathy panel containing definitive HCM genes, including TNNT2, MYBPC3, MYH7, TNNI3, TPM1, ACTC1, MYL2, and MYL3, with phenocopy genes selected by clinical context. Sequencing plus deletion/duplication analysis is preferred. WES/WGS can be useful when panel testing is negative or the phenotype is atypical, but interpretation of deep-intronic, structural, and incidental variants remains challenging. CMA, karyotyping, FISH, mitochondrial DNA, and repeat-expansion testing are not first-line for isolated HCM2 unless syndromic features suggest another diagnosis.

Once a familial TNNT2 P/LP variant is identified, targeted cascade testing is appropriate. Relatives who test negative for that variant can usually be released from serial HCM surveillance; genotype-positive relatives require longitudinal ECG/imaging. A VUS should not be used for predictive testing. Genetic testing supports family screening and phenocopy discrimination but does not replace phenotype-led sudden-death assessment. (sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12, nakamura2025cardiacmyosininhibitors pages 2-4)

Differential diagnosis

Exclude hypertensive heart disease, aortic stenosis, athletic remodeling, transthyretin or light-chain amyloidosis, Fabry disease, glycogen-storage disease including PRKAG2 and LAMP2 disorders, mitochondrial disease, RASopathies, and infiltrative/storage disease. Red flags include multisystem disease, conduction disease, pre-excitation, neuropathy, renal dysfunction, low-voltage ECG despite thick walls, and atypical CMR enhancement.

11. Outcome and prognosis

Many patients have normal or near-normal longevity with contemporary surveillance and treatment, but individual risk varies. Major morbid outcomes are ventricular arrhythmia/sudden death, atrial fibrillation and stroke, progressive heart failure, LV apical aneurysm, and end-stage systolic dysfunction.

TNNT2 should not be treated as uniformly malignant: risk is variant- and phenotype-dependent. Nevertheless, thin-filament TNNT2 variants have been associated with sudden death despite mild LVH, and Δ160E has been associated with adverse remodeling and advanced heart failure. (kondo2022humaninducedpluripotentstem pages 1-2, shafaattalab2021mechanismsofarrhythmogenicity pages 1-2)

Prognostic assessment integrates prior cardiac arrest or sustained VT, unexplained syncope, family history of HCM-related sudden death, maximal wall thickness, LV apical aneurysm, LVEF, nonsustained VT, LVOT gradient, left-atrial size, fibrosis/LGE, and age. The ESC HCM Risk-SCD framework considers an ICD at a five-year risk of 4–6% and recommends it at ≥6%, while US guidance uses major risk markers and shared decision-making. (sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12)

No TNNT2-specific circulating prognostic biomarker is clinically validated. Genotype is useful context but should not be the sole basis for ICD implantation.

12. Treatment

Treatment is phenotype-directed; no approved therapy corrects the TNNT2 allele.

Pharmacotherapy

• Non-vasodilating beta-blockers are first-line for symptomatic obstructive HCM; verapamil or diltiazem are alternatives when appropriate. Disopyramide may be added for persistent obstruction. Suggested NCIT-style concepts: Beta-Blocker Therapy, Calcium Channel Blocker Therapy, Disopyramide Therapy. (nakamura2025cardiacmyosininhibitors pages 11-13, nakamura2025cardiacmyosininhibitors pages 2-4)
• Diuretics may be used cautiously for congestion. Atrial fibrillation generally warrants anticoagulation irrespective of conventional CHA₂DS₂-VASc thresholds.
• Standard heart-failure therapy is used when systolic dysfunction develops, with specialist oversight.

Cardiac myosin inhibitors

Mavacamten directly reduces cardiac myosin ATPase activity and excessive actin–myosin cross-bridging. In EXPLORER-HCM, 37% versus 17% achieved the primary exercise/NYHA endpoint; post-exercise LVOT gradient fell approximately 36 mmHg more than placebo. In VALOR-HCM, only 17.9% versus 76.8% remained eligible for septal reduction after 16 weeks. (nakamura2025cardiacmyosininhibitors pages 13-14, ottaviani2023revisitingdiagnosisand pages 23-24)

Long-term MAVA-LTE data over a median 166.1 weeks found 77.9% improved by at least one NYHA class, LVOT gradients declined 40.3–55.3 mmHg, and 82.7% reached a Valsalva gradient <30 mmHg. Transient LVEF <50% occurred in 8.7% and resolved after interruption; this necessitates protocolized echocardiographic monitoring and drug-interaction review. (nakamura2025cardiacmyosininhibitors pages 16-18)

Aficamten, a shorter-half-life myosin inhibitor, reduced LVOT gradients by approximately 27–53 mmHg in REDWOOD/FOREST studies and improved exercise capacity and symptoms in obstructive HCM. These agents treat the HCM physiology, not specifically TNNT2-HCM, and are not curative. (hou2025cardiacmyosininhibitors pages 12-13, ottaviani2023revisitingdiagnosisand pages 23-24)

Mavacamten is teratogenic and contraindicated in pregnancy; reproductive counseling and effective contraception are required. (sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12)

Procedures and devices

Severe drug-refractory symptomatic LVOTO is treated with surgical septal myectomy or, in selected adults, alcohol septal ablation. A contemporary synthesis reported obstruction control in approximately 88% after myectomy and 79% after alcohol ablation; center expertise is crucial. (nakamura2025cardiacmyosininhibitors pages 11-13)

An implantable cardioverter-defibrillator is indicated after cardiac arrest/sustained VT and considered for primary prevention according to risk markers. Heart transplantation is reserved for refractory end-stage disease.

Experimental therapy

Calcium desensitizers, allele-specific silencing, RNA therapy, gene editing, and gene replacement remain preclinical for TNNT2-HCM. Epigallocatechin-3-gallate rescued calcium-decay abnormalities in Δ160E iPSC cardiomyocytes, but there is no clinical efficacy evidence. (kondo2022humaninducedpluripotentstem pages 1-2)

13. Prevention

Primary prevention of the inherited allele is not possible after conception. Reproductive options include genetic counseling, prenatal diagnosis, and preimplantation genetic testing when a familial P/LP variant is known.

Secondary prevention centers on cascade genetic testing, serial ECG/echo surveillance of genotype-positive relatives, early recognition of obstruction/arrhythmia, ambulatory rhythm monitoring, and periodic CMR when clinically indicated. Population or newborn screening is not standard.

Tertiary prevention includes sudden-death risk assessment and ICD placement, anticoagulation for atrial fibrillation, management of obstruction and heart failure, avoidance of dehydration and stimulants, and individualized exercise plans. Mild-to-moderate exercise is generally beneficial; blanket inactivity is not recommended. (sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12)

Vaccination has no disease-specific role beyond routine cardiovascular health. There is no infectious prophylaxis or environmental-control program specific to HCM2.

14. Other species and naturally occurring disease

Naturally occurring cardiomyopathies occur in cats and other animals, but a well-established, breed-specific naturally occurring TNNT2-HCM2 orthologous disease was not identified in the retrieved evidence. Therefore no VBO breed annotation should be asserted without OMIA-level verification. The disease is noninfectious and nonzoonotic.

Orthologous troponin-T biology is highly conserved. A CRISPR-generated zebrafish tnnt2a RK94del heterozygote developed early diastolic dysfunction and abnormal calcium dynamics by five days postfertilization; adults showed atrial enlargement, reduced ventricular size, myocardial stress, fibrosis, and progressive heart failure. This experimentally induced model supports cross-species conservation of thin-filament calcium dysregulation. (kamel2021aheterozygousmutation pages 1-2)

15. Model organisms and experimental systems

• Human iPSC cardiomyocytes, TNNT2 I79N: CRISPR isogenic cells reproduce increased calcium sensitivity, slowed calcium off-rate, action-potential triangulation, alternans, disarray, and NPPA/NPPB/ECM transcriptional activation. Strength: human genetic background and electrophysiology. Limitation: immature cardiomyocyte phenotype. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2)
• Human iPSC cardiomyocytes, Δ160E: heterozygous and homozygous isogenic lines show dose-dependent calcium-decay prolongation, relaxation impairment, NFATc1 activation, hypertrophy, and CaMKII/phospholamban signaling. Useful for calcium-desensitizer screening. (kondo2022humaninducedpluripotentstem pages 1-2)
• Human embryonic-stem-cell cardiomyocytes and engineered tissue, R92Q: reproduce calcium dysregulation, hypertrophic-marker expression, adrenergic hypersensitivity, altered contractility, and myofilament disorganization; useful for drug efficacy and cardiotoxicity studies. (cai2020establishinganew pages 21-25)
• Mouse Tnnt2 models: I79N, R92Q, and related transgenic/knock-in models reproduce arrhythmogenicity, calcium sensitization, hypertrophy, and remodeling. Advantages are intact physiology and longitudinal testing; limitations include species-specific heart rate, calcium handling, and transgene dosage. (dolder2025experimentalmodelsof pages 36-36)
• Zebrafish tnnt2a RK94del: offers rapid in-vivo imaging and compound screening but differs substantially from human chamber anatomy and electrophysiology. (kamel2021aheterozygousmutation pages 1-2)

Recent developments and expert assessment

The most important 2023–2024 advance is recognition that genetic HCM penetrance depends strongly on ascertainment. The January 2024 Circulation meta-analysis reviewed 455 manuscripts and estimated TNNT2 penetrance near 60% in cascade-screened relatives, but only about 11% penetrance for incidentally identified sarcomeric P/LP variants in population studies. This supports expert recommendations that genotype be interpreted alongside pedigree and longitudinal phenotype rather than deterministically. DOI: https://doi.org/10.1161/CIRCULATIONAHA.123.065987, published January 2024. (topriceanu2024metaanalysisofpenetrance pages 1-2)

The 2023–2024 guideline era also normalized moderate exercise, emphasized shared ICD decisions and CMR fibrosis assessment, and incorporated cardiac myosin inhibition for symptomatic obstructive HCM. However, these advances are not genotype-specific, and no evidence yet shows that TNNT2 carriers respond differently from other sarcomeric-HCM patients. (nakamura2025cardiacmyosininhibitors pages 13-14, sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12)

The central expert interpretation is therefore: TNNT2 genotype establishes cause and enables cascade screening, but surveillance, prognosis, and treatment remain phenotype-led. Variant-level functional data can be highly informative, yet should not be generalized across all TNNT2 alleles. The largest unresolved needs are variant-specific natural-history cohorts, validated polygenic/environmental modifiers, mature human myocardial models, and trials of causal RNA or gene therapies.

References

1. (OpenTargets Search: hypertrophic cardiomyopathy-TNNT2): Open Targets Query (hypertrophic cardiomyopathy-TNNT2, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (topriceanu2024metaanalysisofpenetrance pages 1-2): Constantin-Cristian Topriceanu, Alexandre C. Pereira, James C. Moon, Gabriella Captur, and Carolyn Y. Ho. Meta-analysis of penetrance and systematic review on transition to disease in genetic hypertrophic cardiomyopathy. Circulation, 149:107-123, Jan 2024. URL: https://doi.org/10.1161/circulationaha.123.065987, doi:10.1161/circulationaha.123.065987. This article has 105 citations and is from a highest quality peer-reviewed journal.

3. (kondo2022humaninducedpluripotentstem pages 1-2): Takumi Kondo, Shuichiro Higo, Mikio Shiba, Yasuaki Kohama, Satoshi Kameda, Tomoka Tabata, Hiroyuki Inoue, Shota Okuno, Shou Ogawa, Satoki Nakamura, Maki Takeda, Emiko Ito, Junjun Li, Li Liu, Yuki Kuramoto, Jong-Kook Lee, Seiji Takashima, Shigeru Miyagawa, Yoshiki Sawa, Shungo Hikoso, and Yasushi Sakata. Human-induced pluripotent stem cell–derived cardiomyocyte model for tnnt2 δ160e-induced cardiomyopathy. Circulation: Genomic and Precision Medicine, Oct 2022. URL: https://doi.org/10.1161/circgen.121.003522, doi:10.1161/circgen.121.003522. This article has 20 citations.

4. (shafaattalab2021mechanismsofarrhythmogenicity pages 1-2): Sanam Shafaattalab, Alison Y Li, Marvin G Gunawan, BaRun Kim, Farah Jayousi, Yasaman Maaref, Zhen Song, James N Weiss, R. John Solaro, Zhilin Qu, and Glen F Tibbits. Mechanisms of arrhythmogenicity of hypertrophic cardiomyopathy-associated troponin t (tnnt2) variant i79n. Frontiers in Cell and Developmental Biology, Dec 2021. URL: https://doi.org/10.3389/fcell.2021.787581, doi:10.3389/fcell.2021.787581. This article has 38 citations.

5. (cai2020establishinganew pages 21-25): Huanhuan Cai, Bin Li, Aobing Bai, Jie Huang, Yongkun Zhan, Ning Sun, Qianqian Liang, and Chen Xu. Establishing a new human hypertrophic cardiomyopathy-specific model using human embryonic stem cells. Feb 2020. URL: https://doi.org/10.1016/j.yexcr.2019.111736, doi:10.1016/j.yexcr.2019.111736. This article has 9 citations and is from a peer-reviewed journal.

6. (nakamura2025cardiacmyosininhibitors pages 2-4): Kazufumi Nakamura, Takahiro Okumura, Seiya Kato, Kenji Onoue, Toru Kubo, Hidemichi Kouzu, Toshiyuki Yano, and Takayuki Inomata. Cardiac myosin inhibitors in hypertrophic cardiomyopathy: from sarcomere to clinic. International Journal of Molecular Sciences, 26:9347, Sep 2025. URL: https://doi.org/10.3390/ijms26199347, doi:10.3390/ijms26199347. This article has 6 citations.

7. (kamel2021aheterozygousmutation pages 1-2): Sarah M. Kamel, Charlotte D. Koopman, Fabian Kruse, Sven Willekers, Sonja Chocron, and Jeroen Bakkers. A heterozygous mutation in cardiac troponin t promotes ca2+ dysregulation and adult cardiomyopathy in zebrafish. Journal of Cardiovascular Development and Disease, 8:46, Apr 2021. URL: https://doi.org/10.3390/jcdd8040046, doi:10.3390/jcdd8040046. This article has 18 citations.

8. (nakamura2025cardiacmyosininhibitors pages 13-14): Kazufumi Nakamura, Takahiro Okumura, Seiya Kato, Kenji Onoue, Toru Kubo, Hidemichi Kouzu, Toshiyuki Yano, and Takayuki Inomata. Cardiac myosin inhibitors in hypertrophic cardiomyopathy: from sarcomere to clinic. International Journal of Molecular Sciences, 26:9347, Sep 2025. URL: https://doi.org/10.3390/ijms26199347, doi:10.3390/ijms26199347. This article has 6 citations.

9. (ottaviani2023revisitingdiagnosisand pages 23-24): Andrea Ottaviani, Davide Mansour, Lorenzo V. Molinari, Kristian Galanti, Cesare Mantini, Mohammed Y. Khanji, Anwar A. Chahal, Marco Zimarino, Giulia Renda, Luigi Sciarra, Francesco Pelliccia, Sabina Gallina, and Fabrizio Ricci. Revisiting diagnosis and treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Journal of Clinical Medicine, 12:5710, Sep 2023. URL: https://doi.org/10.3390/jcm12175710, doi:10.3390/jcm12175710. This article has 43 citations.

10. (dolder2025experimentalmodelsof pages 36-36): Floor W. van den Dolder, Rafeeh Dinani, Vincent A.J. Warnaar, Sofija Vučković, Adriana S. Passadouro, Ali A. Nassar, Azhaar X. Ramsaroep, George B. Burchell, Linda J. Schoonmade, Jolanda van der Velden, and Birgit Goversen. Experimental models of hypertrophic cardiomyopathy. JACC: Basic to Translational Science, 10:511-546, Jan 2025. URL: https://doi.org/10.1016/j.jacbts.2024.10.017, doi:10.1016/j.jacbts.2024.10.017. This article has 12 citations.

11. (sanghvi2025hypertrophiccardiomyopathymanagement pages 11-12): Mihir M Sanghvi, Eamon Dhall, C Anwar A. Chahal, Constantinos O'Mahony, Saidi A Mohiddin, Konstantinos Savvatis, Fabrizio Ricci, Patricia B Munroe, Steffen E Petersen, Nay Aung, and Mohammed Y Khanji. Hypertrophic cardiomyopathy management: a systematic review of the clinical practice guidelines and recommendations. European heart journal. Quality of care & clinical outcomes, Jan 2025. URL: https://doi.org/10.1093/ehjqcco/qcae117, doi:10.1093/ehjqcco/qcae117. This article has 15 citations.

12. (nakamura2025cardiacmyosininhibitors pages 11-13): Kazufumi Nakamura, Takahiro Okumura, Seiya Kato, Kenji Onoue, Toru Kubo, Hidemichi Kouzu, Toshiyuki Yano, and Takayuki Inomata. Cardiac myosin inhibitors in hypertrophic cardiomyopathy: from sarcomere to clinic. International Journal of Molecular Sciences, 26:9347, Sep 2025. URL: https://doi.org/10.3390/ijms26199347, doi:10.3390/ijms26199347. This article has 6 citations.

13. (nakamura2025cardiacmyosininhibitors pages 16-18): Kazufumi Nakamura, Takahiro Okumura, Seiya Kato, Kenji Onoue, Toru Kubo, Hidemichi Kouzu, Toshiyuki Yano, and Takayuki Inomata. Cardiac myosin inhibitors in hypertrophic cardiomyopathy: from sarcomere to clinic. International Journal of Molecular Sciences, 26:9347, Sep 2025. URL: https://doi.org/10.3390/ijms26199347, doi:10.3390/ijms26199347. This article has 6 citations.

14. (hou2025cardiacmyosininhibitors pages 12-13): Lianglei Hou, Bin Lin, Xiaojun Ji, and Anwu Huang. Cardiac myosin inhibitors in hypertrophic cardiomyopathy: clinical advances and therapeutic prospects. Drug Design, Development and Therapy, Volume 19:9367-9385, Oct 2025. URL: https://doi.org/10.2147/dddt.s555335, doi:10.2147/dddt.s555335. This article has 7 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.